SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.


Journal

American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369

Informations de publication

Date de publication:
01 01 2022
Historique:
revised: 17 10 2021
received: 05 09 2021
accepted: 20 10 2021
pubmed: 26 10 2021
medline: 28 12 2021
entrez: 25 10 2021
Statut: ppublish

Résumé

This is a multicenter prospective observational study that included a large cohort (n = 397) of allogeneic (allo-HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3-6 weeks after complete severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1, 2021, to July 20, 2021. Most patients (n = 387, 97.4%) received mRNA-based vaccines. Most of the recipients (93%) were vaccinated more than 1 year after transplant. Detectable SARS-CoV-2-reactive antibodies were observed in 242 (78%) of allo-HSCT and in 73 (85%) of ASCT recipients. Multivariate analysis in allo-HSCT recipients identified lymphopenia < 1 × 10

Identifiants

pubmed: 34695229
doi: 10.1002/ajh.26385
pmc: PMC8646900
doi:

Substances chimiques

Antibodies, Viral 0
COVID-19 Vaccines 0

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

30-42

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):e801-e809
pubmed: 34376375
Bone Marrow Transplant. 2001 Sep;28(5):479-84
pubmed: 11593321
Bone Marrow Transplant. 2020 Dec;55(12):2261-2269
pubmed: 32415227
Clin Infect Dis. 2019 May 17;68(11):1894-1903
pubmed: 30239624
Exp Hematol Oncol. 2020 Aug 25;9:21
pubmed: 32864192
J Hematol Oncol. 2020 Oct 8;13(1):133
pubmed: 33032660
Vaccine. 2008 Sep 12;26 Suppl 4:D35-40
pubmed: 19230157
Transplantation. 2008 Jul 27;86(2):257-63
pubmed: 18645488
Br J Haematol. 2021 Oct;195(2):186-193
pubmed: 34196388
Blood. 2021 Oct 7;138(14):1278-1281
pubmed: 34339501
Kidney Int Rep. 2021 Sep;6(9):2292-2304
pubmed: 34250319
Transplant Cell Ther. 2021 Sep;27(9):788-794
pubmed: 34214738
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
Exp Hematol Oncol. 2020 Dec 18;9(1):37
pubmed: 33339537
Nat Microbiol. 2021 Sep;6(9):1140-1149
pubmed: 34290390
Transpl Infect Dis. 2018 Aug;20(4):e12926
pubmed: 29809298
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Clin Infect Dis. 2000 Feb;30(2):342-8
pubmed: 10671339
Leukemia. 2021 Oct;35(10):2885-2894
pubmed: 34079042
Transplant Cell Ther. 2021 Nov;27(11):938.e1-938.e6
pubmed: 34274492
Lancet Haematol. 2021 Mar;8(3):e185-e193
pubmed: 33482113
Acta Haematol. 1994;91(3):115-8
pubmed: 8091931
Medicine (Baltimore). 2006 Sep;85(5):278-287
pubmed: 16974212
EJHaem. 2021 Jun 01;2(3):520-524
pubmed: 34226903
Am J Hematol. 2021 Oct 1;96(10):1195-1203
pubmed: 34185336
Lancet. 2021 Jul 24;398(10297):298-299
pubmed: 34270933
Cancer Cell. 2021 Aug 9;39(8):1031-1033
pubmed: 34331856
Lancet Haematol. 2021 Aug;8(8):e583-e592
pubmed: 34224668
Blood. 1993 Sep 1;82(5):1672-8
pubmed: 8395913
Am J Hematol. 2022 Jan 1;97(1):30-42
pubmed: 34695229
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Ann Intern Med. 2021 Sep;174(9):1330-1332
pubmed: 34125572
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet Infect Dis. 2019 Jun;19(6):e200-e212
pubmed: 30744963
Bone Marrow Transplant. 1993 Jan;11(1):1-5
pubmed: 8431706
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155
Front Immunol. 2019 Mar 08;10:428
pubmed: 30906300

Auteurs

José Luis Piñana (JL)

Hematology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Fundación INCLIVA, Instituto de Investigación Sanitaria Hospital Clínico, Universitario de Valencia, Valencia, Spain.

Lucia López-Corral (L)

Hematology Division, Hospital Universitario de Salamanca, Salamanca, Spain.

Rodrigo Martino (R)

Hematology Division, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Juan Montoro (J)

Hematology Division, Hospital universitario y politécnico La Fe, Valencia, Spain.

Lourdes Vazquez (L)

Hematology Division, Hospital Universitario de Salamanca, Salamanca, Spain.

Ariadna Pérez (A)

Hematology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Fundación INCLIVA, Instituto de Investigación Sanitaria Hospital Clínico, Universitario de Valencia, Valencia, Spain.

Gabriel Martin-Martin (G)

Hematology Division, Hospital Universitario de Salamanca, Salamanca, Spain.

Ana Facal-Malvar (A)

Hematology Division, Hospital universitario y politécnico La Fe, Valencia, Spain.

Elena Ferrer (E)

Hematology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.

María-Jesús Pascual (MJ)

Hematology Division, Hospital Regional Universitario Carlos Haya, Malaga, Spain.

Gabriela Sanz-Linares (G)

Hematology Division, Institut Català Oncologia-Hospital Duran i reynals, Barcelona, Spain.

Beatriz Gago (B)

Hematology Division, Hospital Regional Universitario Carlos Haya, Malaga, Spain.

Andrés Sanchez-Salinas (A)

Hematology Division, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.

Lucia Villalon (L)

Hematology Division, Hospital Universitario Fundación Alcorcón, Madrid, Spain.

Venancio Conesa-Garcia (V)

Hematology Division, Hospital General Universitari d'Elx, Elche, Spain.

Maria T Olave (MT)

Hematology Division, Hospital Clínico Universitario Lozano Blesa, IIS Aragon, Zaragoza, Spain.

Javier López-Jimenez (J)

Hematology Division, Hospital Ramon y Cajal, Madrid, Spain.

Sara Marcos-Corrales (S)

Hematology Division, Hospital Universitario de Salamanca, Salamanca, Spain.

Marta García-Blázquez (M)

Hematology Division, Hospital Universitario de Salamanca, Salamanca, Spain.

Valentín Garcia-Gutiérrez (V)

Hematology Division, Hospital Ramon y Cajal, Madrid, Spain.

José Ángel Hernández-Rivas (JÁ)

Hematology Division, Hospital Universitario Infanta Leonor, Madrid, Spain.

Ana Saus (A)

Hematology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Fundación INCLIVA, Instituto de Investigación Sanitaria Hospital Clínico, Universitario de Valencia, Valencia, Spain.

Ildefonso Espigado (I)

Hematology Division, Universidad de Sevilla, Hospital Universitario Virgen Macarena-Hospital Universitario Virgen del Rocío, IBiS/CSIC, Sevilla, Spain.

Carmen Alonso (C)

Hematology Division, Hospital Arnau de Vilanova, Valencia, Spain.

Rafael Hernani (R)

Hematology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Fundación INCLIVA, Instituto de Investigación Sanitaria Hospital Clínico, Universitario de Valencia, Valencia, Spain.

Carlos Solano (C)

Hematology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Fundación INCLIVA, Instituto de Investigación Sanitaria Hospital Clínico, Universitario de Valencia, Valencia, Spain.
Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.

Blanca Ferrer-Lores (B)

Hematology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Fundación INCLIVA, Instituto de Investigación Sanitaria Hospital Clínico, Universitario de Valencia, Valencia, Spain.

Manuel Guerreiro (M)

Hematology Division, Hospital universitario y politécnico La Fe, Valencia, Spain.

Montserrat Ruiz-García (M)

Microbiology department, Hospital General universitari d'Elx, Elche, Spain.

Juan Luis Muñoz-Bellido (JL)

Microbiology department, Hospital Universitario de Salamanca, Salamanca, Spain.

David Navarro (D)

Fundación INCLIVA, Instituto de Investigación Sanitaria Hospital Clínico, Universitario de Valencia, Valencia, Spain.
Microbiology department, Hospital Clinico Universitario de Valencia, Valencia, Spain.

Angel Cedillo (A)

Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH), Madrid, Spain.

Anna Sureda (A)

Hematology Division, Institut Català Oncologia-Hospital Duran i reynals, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH